Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R21DA043963 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Drug Abuse (NIDA) | NIH |
Not provided
Not provided
Not provided
Not provided
All participants will be healthy volunteers and all procedures will be completed for research purposes only. Two groups will be recruited, females who use cannabis (marijuana, MJ), and female who do not use cannabis (controls). Female MJ users will be enrolled in a protocol that includes an outpatient drug administration session and a 4-day/3-night inpatient stay on the Johns Hopkins Bayview Clinical Research Unit (CRU). During outpatient visits, MJ users will have an MRI, and complete MJ self-administration and cognitive performance sessions. MJ users will then reside on the CRU,and complete MJ abstinence, and self-report instruments for withdrawal discomfort. A positron emission tomography (PET) scan of brain cannabinoid type 1 receptors will also be completed. Non-users will complete MRI, PET imaging and cognitive testing under an outpatient protocol (no MJ administration).
The primary goals of this project are to examine whether use of cannabis alters brain cannabinoid type 1 receptor (CB1R) availability in females, and if severity of cannabis withdrawal is correlated with CB1 receptor availability. CB1R are widely distributed in the human brain and can be quantified using PET imaging with the radiotracer 11C-OMAR (Carbon-11-OMAR). The effects MJ use on brain CB1R have not been studied in females. The current study will enroll 10 female MJ users in an inpatient protocol that includes administration of smoked MJ, followed by monitored abstinence with daily behavioral assessments, and PET imaging with 11C-OMAR. PET data will collected in 10 matched controls for comparison. The proposed study is an important first step to determine whether localized CB1R changes in female MJ users help explain, and provide a neurobiological target for intervention. Results will increase knowledge of cannabinoid mechanisms of cannabis use and severity of dependence in females, an understudied population.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cannabis users | Active Comparator | Smoked Cannabis plant material (0 and 25 mg THC) will be administered to volunteers who are regular cannabis users. Cannabis users will also complete a PET scan where 20 millicurie of 11C-OMAR |
|
| Nonuser controls | Active Comparator | No cannabis administration. Non-user controls will complete a PET scan where 20 millicuries of 11C-OMAR |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 11C-OMAR | Drug | 11C-OMAR is a PET radiotracer that binds to cannabinoid type 1 receptors (CB1R). It is an analog of the CB1R antagonist/inverse agonist rimonabant. 11C-OMAR was developed, synthesized and validated for inhuman use at the Johns Hopkins University PET center. |
| Measure | Description | Time Frame |
|---|---|---|
| Distribution Volume (VT) | Distribution Volume (VT) is the quantification of 11C-OMAR binding to the CB1R; Per our statistical plan we examined VT for eight volumes of interest in the brain (ventral striatum, amygdala, putamen, cingulate, globus pallidus, insula, frontal cortex, and hippocampus) as well as the composite VT for the brain. The unit of measure is mL/cm^3. | Collected during 90-min PET study |
| Measure | Description | Time Frame |
|---|---|---|
| Peak Change From Baseline Marijuana Withdrawal Discomfort Score | Marijuana withdrawal discomfort will be self-reported using the marijuana withdrawal checklist, available via PhenXToolkit.org. Items are: depressed mood, irritability, nervousness/anxiety, restlessness, increased aggression, increased anger, violent outbursts, nausea, decreased appetite, stomach pain, shakiness, sweating, sleep difficulty, strange/wild dreams, craving to smoke cannabis, diarrhea/loose stools, dizziness, muscle spasms/aches, hiccups, stuffy nose, feverish feeling, hot flashes, chills, increased appetite, headaches, fatigue/tiredness, yawning, difficulty concentrating, general physical discomfort, and other. Each item is rated as 0=none, 1=mild, 2=moderate, or 3=severe. A sum score is calculated from items that are valid, reliable cannabis withdrawal symptoms (Budney et al, 2003, Journal of Abnormal Psychology,112(3): 393-402). A higher score represents more severe withdrawal. Scores range from 0-36. |
Not provided
Female, healthy adult volunteers who are either MJ users and nonusers (controls)
18-45 years of age
serum creatinine and hepatic enzymes (AST, ALT) must be within the normal limits
Women of child bearing potential must meet one of the following three criteria:
1. negative pregnancy test by serum pregnancy test 2 .Following a reliable method of birth control 3. Agreeing to follow a reliable method of birth control during the study and for 1 month following all study procedures
Additional inclusion criteria for MJ users
Additional inclusion non-users
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Elise Weerts, Ph.D. | Johns Hopkins University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Johns Hopkins Bayview Medical Center | Baltimore | Maryland | 21224 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
15 participants (8 females, 7 males) did not start, but were historical controls included for data analysis
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Female Cannabis Users | Females with cannabis use disorder (CUD): reported using cannabis on average ≥ 25 days per month in the past 3 months, positive test for cannabis on a urine screen, met DSM-V criteria for moderate or severe CUD, and reported ≥ 2 cannabis withdrawal symptoms during a past cannabis abstinence period. |
| FG001 | Female Healthy Nonuser Controls | Female healthy controls (nonusers): no cannabis use for ≥ 12 months, ≤ 5 lifetime cannabis uses, negative urine test for cannabis |
| FG002 | Female Non-user Healthy Historical Controls | Female non-users who were not enrolled in the study but were collapsed into the same category as contemporary controls (n = 2) bringing total number of female non-user healthy controls to 10. |
| FG003 | Male Healthy Historical Controls | Male healthy historical controls (nonusers) who were not enrolled in the study but were used for gender comparison |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
There were 21 female cannabis users and 7 female healthy control nonusers enrolled. Of these, 10 of the female cannabis users and 2 healthy control female nonusers completed the full protocol and were included in the analysis. Due to low recruitment for healthy controls, 8 historical female healthy controls were included in analysis. We also conducted an analysis that compared all female controls (n=10; 2 healthy controls and 8 matched historical controls) with male historical controls.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Female Cannabis Users With CUD | Smoked Cannabis plant material (0 and 25 mg THC) will be administered to volunteers who are regular cannabis users. Cannabis users will also complete a PET scan where 20 millicurie of 11C-OMAR 11C-OMAR: 11C-OMAR is a PET radiotracer that binds to cannabinoid type 1 receptors (CB1R). It is an analog of the CB1R antagonist/inverse agonist rimonabant. 11C-OMAR was developed, synthesized and validated for inhuman use at the Johns Hopkins University PET center. Cannabis: Cannabis will be administered to cannabis users. Doses include 0 and 25 mg THC. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Distribution Volume (VT) | Distribution Volume (VT) is the quantification of 11C-OMAR binding to the CB1R; Per our statistical plan we examined VT for eight volumes of interest in the brain (ventral striatum, amygdala, putamen, cingulate, globus pallidus, insula, frontal cortex, and hippocampus) as well as the composite VT for the brain. The unit of measure is mL/cm^3. | Nonuser female healthy controls group includes 2 contemporary female controls and 8 historical female controls. | Posted | Mean | Standard Error | mL/cm^3 | Collected during 90-min PET study |
|
2 weeks
Adverse event data not available for historical control males or historical control females.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Females With Cannabis Use Disorder | Smoked Cannabis plant material (0 and 25 mg THC) will be administered to volunteers who are regular cannabis users. Cannabis users will also complete a PET scan. |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Elise M. Weerts, PhD, Professor | Johns Hopkins School of Medicine | 443-550-2781 | eweerts@jhmi.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Aug 15, 2017 | Nov 9, 2022 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D002189 | Marijuana Abuse |
| ID | Term |
|---|---|
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C515663 | 4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide |
| C587251 | nabiximols |
Not provided
Not provided
Not provided
Two groups will be recruited. Female cannabis users and nonusers.
Not provided
Not provided
Cannabis THC content (dose) is masked for participant
|
| Cannabis | Drug | Cannabis will be administered to cannabis users. Doses include 0 and 25 mg THC. |
|
|
| Up to 5 days |
| Physician Decision |
|
| failure to place arterial line |
|
| Withdrawal by Subject |
|
| BG001 | Nonuser Female Healthy Controls (Contemporary and Historical) | No cannabis administration. Non-user controls will complete a PET scan where 20 millicuries of 11C-OMAR. 11C-OMAR: 11C-OMAR is a PET radiotracer that binds to cannabinoid type 1 receptors (CB1R). It is an analog of the CB1R antagonist/inverse agonist rimonabant. 11C-OMAR was developed, synthesized and validated for inhuman use at the Johns Hopkins University PET center. Contemporary and historical female non-user healthy controls were collapsed into one group due to low enrollment of contemporary healthy controls. |
| BG002 | Male Non-user Historical Controls | Historical male non-user healthy controls used for comparison |
| BG003 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Age of first cannabis use | Only 10 participants were cannabis users (healthy controls had used cannabis ≤ 5 times in lifetime); therefore, "age of first cannabis use" data was only collected for the group of cannabis users. | Mean | Standard Deviation | years |
|
| Years of cannabis use | Only 10 participants were cannabis users (healthy controls had used cannabis ≤ 5 times in lifetime); therefore, "years of cannabis use" only applies to the group of cannabis users. | Mean | Standard Deviation | years |
|
| OG001 | Nonuser Female Healthy Controls | No cannabis administration. Non-user controls will complete a PET scan where 20 millicuries of 11C-OMAR 11C-OMAR: 11C-OMAR is a PET radiotracer that binds to cannabinoid type 1 receptors (CB1R). It is an analog of the CB1R antagonist/inverse agonist rimonabant. 11C-OMAR was developed, synthesized and validated for inhuman use at the Johns Hopkins University PET center. |
| OG002 | Historical Non-user Male Healthy Controls | Healthy, non-user historical male controls |
|
|
|
| Secondary | Peak Change From Baseline Marijuana Withdrawal Discomfort Score | Marijuana withdrawal discomfort will be self-reported using the marijuana withdrawal checklist, available via PhenXToolkit.org. Items are: depressed mood, irritability, nervousness/anxiety, restlessness, increased aggression, increased anger, violent outbursts, nausea, decreased appetite, stomach pain, shakiness, sweating, sleep difficulty, strange/wild dreams, craving to smoke cannabis, diarrhea/loose stools, dizziness, muscle spasms/aches, hiccups, stuffy nose, feverish feeling, hot flashes, chills, increased appetite, headaches, fatigue/tiredness, yawning, difficulty concentrating, general physical discomfort, and other. Each item is rated as 0=none, 1=mild, 2=moderate, or 3=severe. A sum score is calculated from items that are valid, reliable cannabis withdrawal symptoms (Budney et al, 2003, Journal of Abnormal Psychology,112(3): 393-402). A higher score represents more severe withdrawal. Scores range from 0-36. | Females with CUD who completed cannabis administration sessions 1 and 2 | Posted | Mean | Standard Deviation | score on a scale | Up to 5 days |
|
|
|
|
| 0 |
| 21 |
| 0 |
| 21 |
| 0 |
| 21 |
| EG001 | Nonuser Female Healthy Controls | No cannabis administration. Non-user controls will complete a PET scan. | 0 | 7 | 0 | 7 | 0 | 7 |
| EG002 | Historical Female Controls | Historical female controls who completed a PET scan | 0 | 8 | 0 | 8 | 0 | 8 |
| EG003 | Historical Male Controls | Historical male controls who completed a PET scan | 0 | 7 | 0 | 7 | 0 | 7 |
Not provided
Not provided
| Male |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|